Le site du DES d'oncologie de Toulouse

Neurologie

10 articles et 1 document

Articles
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
Neurologie - Publié le 29/10/2019 par Gauthier Glemarec

In the final analysis of this randomized clinical trial of patients with glioblastoma who had received standard radiochemotherapy, the addition of TTFields to maintenance temozolomide chemotherapy v... lire la suite


Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG
Neurologie - Publié le 29/10/2019 par Gauthier Glemarec

Radiation with concurrent and adjuvant (6 cycles) temozolomide (TMZ) is the established standard of postsurgical care for newly diagnosed glioblastoma (GBM). This regimen has been adopted with variat... lire la suite


Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Neurologie - Publié le 29/10/2019 par Gauthier Glemarec

Grade 2 gliomas occur most commonly in young adults and cause progressive neurologic deterioration and premature death. Early results of this trial showed that treatment with procarbazine, lomustine (... lire la suite


Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Neurologie - Publié le 29/10/2019 par Gauthier Glemarec

Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet haemocyanin. In the ACT IV study, ... lire la suite


Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
Neurologie - Publié le 29/10/2019 par Gauthier Glemarec

Glioblastoma is a highly vascularised tumour and there are few treatment options after disease recurrence. Regorafenib is an oral multikinase inhibitor of angiogenic, stromal, and oncogenic receptor ... lire la suite


Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
Neurologie - Publié le 29/10/2019 par Gauthier Glemarec

Glioblastoma is associated with a poor prognosis in the elderly. Survival has been shown to increase among patients 70 years of age or younger when temozolomide chemotherapy is added to standard rad... lire la suite


A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Neurologie - Publié le 29/10/2019 par Gauthier Glemarec

Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclon... lire la suite


Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Neurologie - Publié le 29/10/2019 par Gauthier Glemarec

Standard therapy for newly diagnosed glioblastoma is radiotherapy plus temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab to radiotherapy–temozolomide for ... lire la suite


Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Neurologie - Publié le 29/10/2019 par Gauthier Glemarec

Cilengitide is a selective αvβ3 and αvβ5 integrin inhibitor.
Data from phase 2 trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in combination... lire la suite


protocole STUPP: Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Neurologie - Publié le 01/08/2019 par Céline Dalmasso

protocole STUPP: Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma... lire la suite